Comment from VivoSim Labs Inc.

Summary: VivoSim Labs, Inc., a company developing 3D human tissue models for drug safety, supports the draft guidance and commends the FDA's validation framework. They recommend expanding the guidance to include non-human NAM models, clarifying which contexts of use will be validated, and urging the FDA to require NAM liver toxicity screening for IND applications due to its high predictive accuracy.